Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

Abstract

Objective This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continued SC sarilumab in the open‐label extension (OLE) study EXTEND (NCT01146652). Methods Patients who completed ASCERTAIN were eligible to enroll in EXTEND to receive sarilumab 200 mg SC every 2 weeks (Q2W). Safety and efficacy were reported through 96 weeks in the OLE in patients who switched from tocilizumab IV to sarilumab 200 mg SC Q2W, who switched from sarilumab 150 mg SC Q2W to sarilumab 200 mg SC Q2W, or who continued sarilumab 200 mg SC Q2W. Results Of 175 patients who completed ASCERTAIN, 168 (96%) enrolled in EXTEND, and 38 of these patients (23%) discontinued the OLE. Cumulative sarilumab exposure during follow‐up was 273.7 patient‐years. No new safety signals were identified, infections occurred at a rate of 59.9/100 patient‐years, and there were no cases of grade 4 neutropenia. Efficacy—as assessed by Disease Activity Score (28 joints) based on C‐reactive protein, Clinical Disease Activity Index, and Health Assessment Questionnaire‐Disability Index scores—was sustained over 96 weeks of follow‐up when switching to, or continuing, sarilumab 200 mg SC Q2W. Conclusion Switching from IV to SC interleukin‐6 receptor inhibitor therapy produced no new safety concerns, and clinical efficacy was sustained over 96 weeks of follow‐up. These findings alleviate potential concerns over switching route of administration with interleukin‐6 receptor inhibitor therapy for RA.